CN108572255B - 检测pd-l1+循环肿瘤细胞的试剂在筛选癌症风险个体以及在癌症患者预后中的应用 - Google Patents
检测pd-l1+循环肿瘤细胞的试剂在筛选癌症风险个体以及在癌症患者预后中的应用 Download PDFInfo
- Publication number
- CN108572255B CN108572255B CN201810210273.7A CN201810210273A CN108572255B CN 108572255 B CN108572255 B CN 108572255B CN 201810210273 A CN201810210273 A CN 201810210273A CN 108572255 B CN108572255 B CN 108572255B
- Authority
- CN
- China
- Prior art keywords
- cancer
- tumor cells
- circulating tumor
- ctcs
- reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 22
- 102000008096 B7-H1 Antigen Human genes 0.000 title claims abstract description 11
- 108010074708 B7-H1 Antigen Proteins 0.000 title claims abstract description 11
- 238000004393 prognosis Methods 0.000 title claims abstract description 9
- 238000012216 screening Methods 0.000 title claims abstract description 5
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims description 116
- 206010028980 Neoplasm Diseases 0.000 title abstract description 29
- 201000011510 cancer Diseases 0.000 title abstract description 24
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 206010038111 Recurrent cancer Diseases 0.000 claims abstract description 10
- 230000000306 recurrent effect Effects 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 206010009944 Colon cancer Diseases 0.000 claims description 27
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 27
- 238000001514 detection method Methods 0.000 claims description 12
- 238000012325 curative resection Methods 0.000 claims description 8
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 abstract description 10
- 208000011575 metastatic malignant neoplasm Diseases 0.000 abstract description 10
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 23
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 23
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 14
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 239000012530 fluid Substances 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 9
- 239000000090 biomarker Substances 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102000011782 Keratins Human genes 0.000 description 2
- 108010076876 Keratins Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- 206010064390 Tumour invasion Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000009400 cancer invasion Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000001758 mesenteric vein Anatomy 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Ecology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471083P | 2017-03-14 | 2017-03-14 | |
| US62/471,083 | 2017-03-14 | ||
| US201762584634P | 2017-11-10 | 2017-11-10 | |
| US62/584,634 | 2017-11-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108572255A CN108572255A (zh) | 2018-09-25 |
| CN108572255B true CN108572255B (zh) | 2023-05-16 |
Family
ID=61868129
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810210273.7A Active CN108572255B (zh) | 2017-03-14 | 2018-03-14 | 检测pd-l1+循环肿瘤细胞的试剂在筛选癌症风险个体以及在癌症患者预后中的应用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180267046A1 (enExample) |
| EP (1) | EP3376227B1 (enExample) |
| JP (1) | JP2018155752A (enExample) |
| KR (1) | KR20180105091A (enExample) |
| CN (1) | CN108572255B (enExample) |
| AU (1) | AU2018201819A1 (enExample) |
| CA (1) | CA2998065A1 (enExample) |
| TW (1) | TWI786095B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
| CN111562375B (zh) * | 2020-04-20 | 2022-05-06 | 山东第一医科大学(山东省医学科学院) | 一种检测胃癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法 |
| CN111551718A (zh) * | 2020-04-20 | 2020-08-18 | 山东第一医科大学(山东省医学科学院) | 一种检测前列腺癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法 |
| TWI874453B (zh) * | 2020-09-17 | 2025-03-01 | 日商細胞雲股份有限公司 | 使用末稍血循環腫瘤細胞之解析的癌症治療方法 |
| RU2738563C1 (ru) * | 2020-09-18 | 2020-12-14 | Ен Джун Чой | Способ прогноза малигнизации и ранней диагностики злокачественных опухолей |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010215838A1 (en) * | 2009-02-20 | 2010-08-26 | John Wayne Cancer Institute | B7-H3 antibody coupled bead assay for detection of circulating tumor cells |
| EP3207377B1 (en) * | 2014-10-15 | 2024-11-06 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
-
2018
- 2018-03-13 US US15/919,734 patent/US20180267046A1/en not_active Abandoned
- 2018-03-14 KR KR1020180029879A patent/KR20180105091A/ko not_active Withdrawn
- 2018-03-14 AU AU2018201819A patent/AU2018201819A1/en not_active Abandoned
- 2018-03-14 CN CN201810210273.7A patent/CN108572255B/zh active Active
- 2018-03-14 EP EP18161647.5A patent/EP3376227B1/en active Active
- 2018-03-14 CA CA2998065A patent/CA2998065A1/en active Pending
- 2018-03-14 TW TW107108604A patent/TWI786095B/zh active
- 2018-03-14 JP JP2018046822A patent/JP2018155752A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3376227A1 (en) | 2018-09-19 |
| AU2018201819A1 (en) | 2018-10-04 |
| US20180267046A1 (en) | 2018-09-20 |
| KR20180105091A (ko) | 2018-09-27 |
| CA2998065A1 (en) | 2018-09-14 |
| CN108572255A (zh) | 2018-09-25 |
| TWI786095B (zh) | 2022-12-11 |
| EP3376227B1 (en) | 2024-02-21 |
| TW201902534A (zh) | 2019-01-16 |
| EP3376227C0 (en) | 2024-02-21 |
| JP2018155752A (ja) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer | |
| Catenacci et al. | Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound | |
| Kuske et al. | Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients | |
| Cauley et al. | Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings | |
| CN108572255B (zh) | 检测pd-l1+循环肿瘤细胞的试剂在筛选癌症风险个体以及在癌症患者预后中的应用 | |
| Park et al. | Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma | |
| JP6485759B2 (ja) | 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット | |
| He et al. | Using the new CellCollector to capture circulating tumor cells from blood in different groups of pulmonary disease: a cohort study | |
| Li et al. | Evaluation of sensitivity and specificity of CanPatrol™ technology for detection of circulating tumor cells in patients with non-small cell lung cancer | |
| Chang et al. | PD-L1 expression in Xp11. 2 translocation renal cell carcinoma: indicator of tumor aggressiveness | |
| Häyry et al. | Rapid nodal staging of head and neck cancer surgical specimens with flow cytometric analysis | |
| Koudelakova et al. | Evaluation of HER2 gene status in breast cancer samples with indeterminate fluorescence in situ hybridization by quantitative real-time PCR | |
| CN103384824B (zh) | 癌症诊断方法及其用途 | |
| Roa‐Peña et al. | Keratin 17 testing in pancreatic cancer needle aspiration biopsies predicts survival | |
| Shen et al. | Correlation between human leukocyte antigen-G expression and clinical parameters in oral squamous cell carcinoma | |
| Kim et al. | Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer | |
| Halawa et al. | The role of liquid biopsy in the diagnosis and prognosis of WHO grade 4 astrocytoma | |
| Tkaczuk et al. | The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method | |
| Zhu et al. | [Retracted] Study on PD‐L1 Expression in NSCLC Patients and Related Influencing Factors in the Real World | |
| Donato et al. | Distinctive phenogroup to differentiate diagnosis of cardiac myxoma vs cardiovascular disease examining blood-based circulating cell biomarkers | |
| Mochizuki et al. | Esophagogastric junction carcinomas-discriminating histological types through immunohistochemistry | |
| Ali et al. | Cancer associated macrophage-like cells in metastatic renal cell carcinoma predicts for poor prognosis and tracks treatment response in real time | |
| Nagaiah et al. | Circulating tumor cells in the management of breast cancer | |
| Mastronicola et al. | Detection of disseminated tumor cells in aspirative drains after neck dissection | |
| Ruano et al. | HPV virus and biomarkers of resistance to chemoradiation in circulating tumor cells from patients with squamous cell carcinoma of the anus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |